Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fulvestrant 65Letrozole 55Paclitaxel 54pembrolizumab 42Trastuzumab 42ribociclib 39Specimen Handling 36palbociclib 35Capecitabine 35Carboplatin 34Anastrozole 34Tamoxifen 32exemestane 31abemaciclib 31pertuzumab 29Cyclophosphamide 27Magnetic Resonance Spectroscopy 26trastuzumab deruxtecan 24Radiotherapy 22Surveys and Questionnaires 20Blood Specimen Collection 20olaparib 18Biopsy 18Standard of Care 17Docetaxel 17Taxes 15130-nm albumin-bound paclitaxel 15eribulin 14Methods 14Mastectomy, Segmental 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × fluoromisonidazole × 90 days × Clear all
NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡